
1. General Information
Erbitux is an oncology medicine containing cetuximab, an EGFR-targeting monoclonal antibody. It is administered by intravenous infusion under the supervision of qualified healthcare professionals. It is a prescription medicine and should be used only according to an oncologist's recommendation.
Erbitux may be used alone or together with chemotherapy, radiotherapy or other targeted treatment depending on the cancer type, biomarker status and treatment protocol.
2. Product Information
- Brand name: Erbitux
- Active ingredient: Cetuximab
- Strength: 100 mg
- Dosage form: Concentrate/solution for intravenous infusion
- Drug class: Antineoplastic monoclonal antibody
- Target: Epidermal Growth Factor Receptor (EGFR)
- Route: Intravenous infusion
- Therapeutic areas: Colorectal cancer and squamous cell cancer of the head and neck
The exact presentation, concentration and pack configuration should always be verified against the manufacturer's current product information before listing or supplying the product.
3. Uses of Erbitux 100 mg Injection
Erbitux may be used in:
- Metastatic colorectal cancer in appropriately selected patients whose tumours express EGFR and have suitable RAS biomarker status.
- Combination treatment with irinotecan-based chemotherapy.
- First-line treatment with FOLFOX in appropriate patients.
- Certain patients with metastatic colorectal cancer who have a BRAF V600E mutation, where Erbitux is used with encorafenib-based treatment.
- Squamous cell cancer of the head and neck, including locally advanced disease with radiotherapy and recurrent/metastatic disease with platinum-based chemotherapy.
Treatment selection depends on tumour characteristics and the approved indication in the relevant country.
4. Benefits of Erbitux
The potential benefits of Erbitux include:
- Targets EGFR signalling involved in cancer-cell growth.
- Can help slow progression of certain EGFR-expressing cancers.
- May improve progression-free survival or overall survival in appropriately selected patients.
- Can be combined with chemotherapy or radiotherapy as part of an oncology treatment programme.
- Provides a targeted treatment approach rather than conventional non-specific chemotherapy alone.
The benefit varies considerably according to cancer type, tumour biomarkers, previous treatment and the overall treatment regimen.
5. Side Effects of Erbitux
Like other anticancer medicines, Erbitux can cause adverse reactions. Important possible reactions include:
- Skin reactions, including acne-like rash
- Infusion-related reactions
- Low magnesium levels
- Diarrhoea
- Nausea or vomiting
- Fatigue
- Fever or chills
- Eye-related problems
- Nail or skin changes
- Severe allergic or infusion reactions in some patients
Serious infusion reactions can occur and require immediate medical attention.
6. Common Side Effects
Frequently reported adverse effects include:
- Skin rash
- Acneiform dermatitis
- Dry or irritated skin
- Low blood magnesium
- Fever
- Chills
- Dizziness
- Breathing difficulty associated with infusion reactions
- Diarrhoea
- Nausea
- Fatigue
The exact adverse-effect profile can differ depending on whether Erbitux is administered alone or with chemotherapy or other anticancer medicines.
7. How to Use Erbitux
Erbitux should not be self-administered. It is given as an intravenous infusion by trained healthcare professionals in an appropriate clinical setting.
According to the EMA, Erbitux may be administered once weekly or once every two weeks depending on the treatment regimen. Patients receive medicines before the infusion to reduce the risk of allergic reactions and should be monitored during and after administration.
The dosage and infusion schedule must be determined by the treating oncologist based on the approved regimen and the patient's clinical condition.
8. How Erbitux Works
Cetuximab is a monoclonal antibody that binds to EGFR on the surface of certain cancer cells.
EGFR normally participates in signalling pathways that promote cell growth and survival. By binding to EGFR, cetuximab blocks EGFR signalling and can inhibit processes involved in tumour-cell growth and progression. Cetuximab can also contribute to immune-mediated destruction of EGFR-expressing tumour cells.
9. Safety Advice for Erbitux
- Use Erbitux only under specialist oncology supervision.
- Patients should be evaluated for the appropriate tumour biomarkers before treatment.
- Inform the healthcare team about previous allergic or infusion reactions.
- Patients should be monitored closely during infusion.
- Report breathing difficulty, severe rash, swelling, dizziness or other symptoms suggesting a serious infusion reaction immediately.
- Blood tests may be required during treatment, including monitoring of electrolytes such as magnesium.
- Tell the doctor about all medicines and cancer treatments being taken.
- Do not change the dose or treatment schedule without medical advice.
- Erbitux must not be substituted with another cetuximab product or oncology medicine without confirmation from the treating healthcare professional.
Erbitux is a specialist prescription oncology medicine and should be handled, stored and administered according to the approved product information and local regulations.
10. Frequently Asked Questions
Q1. What is Erbitux 100 mg Injection?
Erbitux 100 mg Injection contains cetuximab, an EGFR-targeting monoclonal antibody used for certain cancers.
Q2. What is the active ingredient in Erbitux?
The active ingredient is cetuximab.
Q3. What cancers can Erbitux treat?
It is used for selected cases of metastatic colorectal cancer and squamous cell cancer of the head and neck.
Q4. Is Erbitux a chemotherapy medicine?
Erbitux is a monoclonal antibody/targeted anticancer medicine. It may be used together with chemotherapy or radiotherapy depending on the indication.
Q5. How is Erbitux administered?
It is administered by intravenous infusion by qualified healthcare professionals.
Q6. Can Erbitux cause skin problems?
Yes. Skin reactions, including acne-like rash, are among the commonly reported adverse effects.
Q7. Does Erbitux require biomarker testing?
For colorectal cancer, treatment selection involves tumour biomarker information such as RAS status; certain indications also involve BRAF V600E status.
Q8. Can Erbitux cause an allergic reaction?
Yes. Infusion-related and sometimes serious hypersensitivity reactions can occur, which is why premedication and clinical monitoring are required.
Q9. Can Erbitux be used during pregnancy?
Pregnancy-related decisions should be discussed with the treating oncologist because anticancer therapy may pose risks to a developing fetus.
Q10. Is Erbitux available internationally?
Availability, registration, importation and prescription requirements differ between countries. International supply should comply with the regulations of both the exporting and importing country.
11. Substitute for Erbitux 100 mg Injection
There is no universally interchangeable substitute for Erbitux. Depending on the cancer type and clinical circumstances, an oncologist may consider other targeted therapies or treatment regimens.
For example, other oncology medicines may target EGFR or different cancer pathways, but they are not automatically substitutes for cetuximab. Treatment choice depends on tumour type, biomarker status, previous treatment, contraindications and local treatment guidelines.
Therefore, a substitute should only be selected by the treating oncologist or qualified healthcare professional.
12. SEO Keywords
Primary Keywords
- Erbitux 100 mg Injection
- Erbitux 100 mg Injection exporter
- Erbitux 100 mg supplier from India
- Erbitux 100 mg pharmaceutical exporter
- Cetuximab 100 mg Injection
- Cetuximab injection supplier India
- Cetuximab 100 mg exporter
- Erbitux injection supplier
- Erbitux oncology medicine supplier
- Erbitux cancer medicine exporter
Long-Tail B2B Keywords
- Erbitux 100 mg Injection pharmaceutical exporter from Nagpur India
- Erbitux 100 mg Injection supplier for international markets
- Cetuximab 100 mg Injection exporter from India
- Erbitux 100 mg oncology medicine supplier India
- Erbitux 100 mg Injection wholesale pharmaceutical supplier
- Cetuximab oncology injection exporter from Nagpur
- Erbitux cancer treatment medicine supplier from India
- Erbitux 100 mg Injection international pharmaceutical supplier
- Cetuximab 100 mg Injection B2B supplier India
- Erbitux 100 mg Injection bulk pharmaceutical supplier
Country-Focused Keywords
- Erbitux 100 mg Injection supplier to USA
- Erbitux 100 mg Injection exporter to UK
- Erbitux 100 mg Injection supplier to Australia
- Erbitux 100 mg Injection exporter to Singapore
- Erbitux 100 mg Injection supplier to Canada
- Erbitux 100 mg Injection exporter to South Korea
- Erbitux 100 mg Injection supplier to UAE
- Cetuximab 100 mg Injection exporter from India to USA
- Cetuximab 100 mg Injection supplier from India to UK
- Cetuximab 100 mg Injection international supplier from India
Phoenix Exim SEO Keywords
- Phoenix Exim Erbitux 100 mg Injection supplier
- Phoenix Exim Cetuximab 100 mg Injection exporter
- Phoenix Exim oncology medicine exporter Nagpur
- Phoenix Exim pharmaceutical exporter from Nagpur India
- Phoenix Exim Erbitux supplier India
- Phoenix Exim cancer medicine exporter India
- Erbitux 100 mg Injection Phoenix Exim Nagpur
- Cetuximab injection Phoenix Exim pharmaceutical supplier
- trusted pharmaceutical exporter Nagpur India Erbitux
- oncology medicine exporter from Nagpur India
Keywords







